Compare
SpyGlass Pharma, Inc. vs Utah Medical Products Inc vs Delcath Systems, Inc. vs NeuroPace Inc
| Latest fiscal year | SpyGlass Pharma, Inc. SGP | Utah Medical Products Inc UTMD | Delcath Systems, Inc. DCTH | NeuroPace Inc NPCE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $38.52M | $85.23M | $99.99M |
| Revenue growth (YoY) | n/a | -5.8% | +129.1% | +25.1% |
| Gross margin | n/a | 57.1% | 86.2% | 77.2% |
| Operating margin | n/a | 29.6% | 0.8% | -16.3% |
| Net margin | n/a | 29.3% | 3.2% | -21.5% |
| Net income | -$39.87M | $11.29M | $2.70M | -$21.46M |
| EPS (Diluted) | -$17.98 | $3.48 | $0.07 | -$0.66 |
| Operating cash flow | -$32.70M | $14.69M | $22.52M | -$11.01M |
| Free cash flow | -$33.49M | $14.32M | $20.97M | -$11.34M |
| Cash & equivalents | $96.36M | $85.76M | $43.45M | $21.69M |
| Total assets | $115.87M | $122.54M | $123.63M | $105.56M |
| Total liabilities | $10.17M | $3.27M | $12.41M | $86.53M |
| Shareholders' equity | -$98.84M | $119.27M | $111.22M | $19.03M |
| Return on year-end equity | n/a | 9.5% | 2.4% | -112.8% |
| Shares outstanding | 2.20M | 3.19M | 34.69M | 33.57M |
Revenue, most recent five fiscal years
| Fiscal year | SpyGlass Pharma, Inc. | Utah Medical Products Inc | Delcath Systems, Inc. | NeuroPace Inc |
|---|---|---|---|---|
| Latest | n/a | $38.52M Ended 2025-12-31 | $85.23M Ended 2025-12-31 | $99.99M Ended 2025-12-31 |
| 1 year earlier | n/a | $40.90M Ended 2024-12-31 | $37.20M Ended 2024-12-31 | $79.91M Ended 2024-12-31 |
| 2 years earlier | n/a | $50.22M Ended 2023-12-31 | $2.06M Ended 2023-12-31 | $65.42M Ended 2023-12-31 |
| 3 years earlier | n/a | $52.28M Ended 2022-12-31 | $2.72M Ended 2022-12-31 | $45.52M Ended 2022-12-31 |
| 4 years earlier | n/a | $49.05M Ended 2021-12-31 | $3.56M Ended 2021-12-31 | $45.18M Ended 2021-12-31 |